LBA1. PEACE-3: Adding 223Ra to enzalutamide significantly improves rPFS and OS in patients with mCRPC

ASCO 2024

Genitourinary Cancer

ARASENS: Adding darolutamide to ADT plus docetaxel delays progression to castrate-resistant disease and improves OS in patients with mHSPC

SABCS 2024

Breast Cancer

EMBER-3: Imlunestrant significantly improves PFS in patients with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations

ASH 2024

Multiple Myeloma (MM)

EMN15/HOVON147: Adding carfilzomib to Rd significantly improves MRD negativity rates in patients with high-risk smoldering multiple myeloma

ESMO 2024

Genitourinary Cancer

ARANOTE: Adding darolutamide to ADT significantly reduced the risk of radiological progression in patients with mHSPC

ESMO 2024

Further Publications

LBA 2. POD1UM-303/InterAACT 2: Adding retifanlimab to chemotherapy improves PFS and shows a trend toward improved OS in SCAC

Genitourinary Cancer

Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis

Eur Urol

Gillessen S, Tombal B, Turco F, Choudhury A, Rodriguez-Vida A, Gallardo E, Velho PI, Nolè F, Cruz F, Loriot Y, McDermott R, Roumeguere T, Daugaard G, Yamamura R, Bompas E, Maroto P, Polo MH, da Trindade KM, Preto DD, Skoneczna I, Lecouvet F, Coens C, Fournier B, Saad F

doi: 10.1016/j.eururo.2024.11.027

ASCO 2024

Genitourinary Cancer

PSMAfore: ¹⁷⁷Lu-PSMA-617 improved time to worsening in HRQoL and pain in taxane-naïve patients with PSMA-positive mCRPC

ESMO 2024

Genitourinary Cancer

EMBARK: Enzalutamide as monotherapy and in combination with leuprolide improves metastasis-free survival in patients with nmHSPC regardless of age

WCLC 2024

Lung, Respiratory and Thoracic Cancer

Related content

ARASENS: Adding darolutamide to ADT plus docetaxel delays progression to castrate-resistant disease and improves OS in patients with mHSPC

EMBER-3: Imlunestrant significantly improves PFS in patients with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations

EMN15/HOVON147: Adding carfilzomib to Rd significantly improves MRD negativity rates in patients with high-risk smoldering multiple myeloma

ARANOTE: Adding darolutamide to ADT significantly reduced the risk of radiological progression in patients with mHSPC

LBA 2. POD1UM-303/InterAACT 2: Adding retifanlimab to chemotherapy improves PFS and shows a trend toward improved OS in SCAC

Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis

PSMAfore: 177Lu-PSMA-617 improved time to worsening in HRQoL and pain in taxane-naïve patients with PSMA-positive mCRPC

EMBARK: Enzalutamide as monotherapy and in combination with leuprolide improves metastasis-free survival in patients with nmHSPC regardless of age

TROPION-Lung01: Datopotamab deruxtecan shows a clinically meaningful trend toward improved OS versus docetaxel in patients with NSCLC

PSMAfore: ¹⁷⁷Lu-PSMA-617 improved time to worsening in HRQoL and pain in taxane-naïve patients with PSMA-positive mCRPC